Mortality in systemic lupus erythematosus: causes, predictors and interventions

Ocampo-Piraquive, Vanessa; Nieto-Aristizábal, Ivana; Cañas, Carlos A.; Tobón, Gabriel J.

doi:10.1080/1744666x.2018.1538789

Cited by 119 publications

(92 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic lupus erythematosus (SLE) is a complicated and multisystem autoimmune disease [1][2][3]. Lupus nephritis (LN) is a serious and common manifestation of SLE, and is characterized by autoantibody-mediated activation of inflammatory response in the kidney [2,4,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

et al. 2020

View full text Add to dashboard Cite

Background: Increased leucine-rich α2-glycoprotein-1 (LRG1) has been observed in various inflammatory and autoimmune diseases. We aimed to explore the expression and role of LRG1 in lupus nephritis (LN). Methods: Plasma LRG1 (pLRG1) was measured by enzyme-linked immunosorbent assay in 101 patients with renal biopsy-proven LN and 21 healthy controls (HC). Relationships between pLRG1 and clinical and pathological characteristics were analyzed. The expression of LRG1 in peripheral blood leukocytes and kidney was detected by flow cytometry, immunohistochemistry and immunofluorescence, respectively. Further cell experiments were focused on the role of LRG1.Results: We found that LRG1 was expressed in plasma, some peripheral blood leukocytes, proximal tubule and several inflammatory cells. The levels of LRG1 in plasma, peripheral blood leukocytes and kidney were elevated in LN patients as compared to HC. Plasma expression levels of LRG1 correlated positively with renal function and renal disease activity, and reflect specific pathologic lesions in the kidneys of patients with LN. Interleukin-1β and interleukin-6, not tumor necrosis factor-α and interferon γ induced the LRG1 expression in human renal tubular epithelial cell line. Moreover, stimulation of recombinant human LRG1 could inhibit late apoptosis, promote proliferation and regulate expression of inflammatory factors and cytokines. Conclusions: Plasma expression levels of LRG1 were associated with renal function, disease activity, and pathology in LN. It might also be involved in renal inflammation, proliferation and apoptosis of endothelial cells. LRG1 might be a potential prognosis novel predictor in LN patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Up to 26% of LN patients develop end-stage renal disease [8,9]. And LN is a major contributor to mortality of SLE despite recent advances [3]. Hence, early diagnosis and management of LN is of tremendous importance.…”

Section: Introductionmentioning

confidence: 99%

Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Predictors of mortality in SLE have been identified as time from onset to diagnosis > 1-year, renal involvement, high SLEDAI (SLE disease activity index) and severe organ involvement. 25 EULAR task force identified infection, hypertension, dyslipidemias, diabetes, osteoporosis and malignancies as comorbidities that increase SLE mortality. 26 A Chinese metanalysis showed that infection causes 25-50% overall mortality.…”

Section: Slementioning

confidence: 99%

Five year retrospective study of mortality in systemic inflammatory rheumatologic disorders

2020

View full text Add to dashboard Cite

Background: Inflammatory systemic rheumatologic disorders are responsible for significant morbidity and premature deaths. The present study was done to assess causes of mortality in these patients.Methods: In the retrospective study, the death records of patients with inflammatory rheumatologic illnesses from January 2012 to January 2017 were studied. The demographic details, disease activity, organ involvement, treatment received and evidence of infection were noted.Results: 50 records were analyzed (25 systemic lupus erythematosus (SLE), 13 rheumatoid arthritis (RA), four immune myositis, three systemic sclerosis (SS), two takayasu’s arteritis (TA), two ankylosing spondylitis (AS) and one granulomatosis with polyangiitis (GPA)). The me an age of death was 39.94 years. Sixteen patients had disease related organ damage, 17 had active disease. Infection was present in 31 patients (gram negative organisms most commonly isolated), being the major contributor of mortality. Only two patients succumbed to acute coronary syndrome.Conclusions: Infection, disease activity and organ damage due to the disease are the major contributors to of death in hospitalized patients with inflammatory rheumatological disorders.

show abstract

“…Причинами смерти больных СКВ являются активация процесса и различные коморбидные состояния (инфекционные, сердечно-сосудистые, почечная недостаточность, поражение нервной системы, печени и др.). Смертность пациентов с СКВ от кардиальной патологии вдвое выше, чем в популяции, сопоставимой по возрасту и полу [4][5][6][7][8][9]. Такие факторы, как период времени от начала болезни до постановки диагноза >1 года, поражение почек, высокий уровень индекса активности и тяжелое поражение органов, могут быть предикторами смертности [8].…”

unclassified

“…Смертность пациентов с СКВ от кардиальной патологии вдвое выше, чем в популяции, сопоставимой по возрасту и полу [4][5][6][7][8][9]. Такие факторы, как период времени от начала болезни до постановки диагноза >1 года, поражение почек, высокий уровень индекса активности и тяжелое поражение органов, могут быть предикторами смертности [8]. Пяти-и десятилетняя выживаемость пациентов с СКВ увеличилась с менее чем 50% в 50-х годах прошлого века до более чем 90% в 80-х годах [9].…”

unclassified

The current status of the problem with systemic lupus erythematosus in Kazakhstan

Исаева¹,

Сапарбаева²,

Исаева³

et al. 2020

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to analyze the provision of medical, including rheumatology, care in Kazakhstan, to study the incidence of systemic lupus erythematosus (SLE), and to develop a registry of patients with this condition.Material and methods. The investigators analyzed the guidelines for the organization of medical, including rheumatology, care in the republic and the official statistical materials of the Ministry of Health of the Republic of Kazakhstan in the period 2012 to 2017. Articles were searched to select activity indices, organ damages and to assess the quality of life and treatment programs in order to create a registry of patients with SLE.Results and discussion. The paper presents the basic principles of providing medical, including rheumatology, care in the republic. It gives data on the issues of providing SLE patients with medicines in outpatient and inpatient settings. It also analyzes trends in the incidence of SLE in the population of Kazakhstan in 2012 to 2017. There were 4,448 SLE patients, including 3,986 women; a comparative analysis of indicators demonstrated a 62.8% increase in the incidence of SLE from 2012 to 2017. The purpose and objectives of the registry of patients with SLE were substantiated.Conclusion. An analysis of morbidity rates suggests that SLE remains to be significant in the republic. The incidence of SLE has been noted to increase in the period from 2012 to 2017; there is a female preponderance (89.6%). The application of the SLE registry in clinical practice will be able to improve the diagnosis of the disease in the early stage and to prevent possible complications.

show abstract

Mortality in systemic lupus erythematosus: causes, predictors and interventions

Cited by 119 publications

References 71 publications

Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

Five year retrospective study of mortality in systemic inflammatory rheumatologic disorders

The current status of the problem with systemic lupus erythematosus in Kazakhstan

Contact Info

Product

Resources

About